Fetal and neonatal alloimmune thrombocytopenia

Seminars in Fetal and Neonatal Medicine

Volumn 21, Issue 1, 2016, Pages 19-27

  Zdravic, Darko ^a,b,c,d   Yougbare, Issaka ^b,c,d   Vadasz, Brian ^a,b,c   Li, Conglei ^a,b,c   Marshall, Alexandra H ^b,c   Chen, Pingguo ^b,c,d   Kjeldsen Kragh, Jens ^b,e   Ni, Heyu ^a,b,c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b Toronto Platelet Immunobiology Group   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

^e Lund University   (Sweden)

Author keywords

Antibody induced immune suppression; Fetal and neonatal alloimmune thrombocytopenia; Intraveneous immunoglobulin G; Platelets; 3 integrin and GPIb

Indexed keywords

BETA3 INTEGRIN; CD36 ANTIGEN; FC RECEPTOR; FIBRINOGEN RECEPTOR; GLUTAMIC ACID; GLYCOPROTEIN IB ALPHA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LYSINE; MATERNAL ANTIBODY; PREDNISONE; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; VERY LATE ACTIVATION ANTIGEN 2;

ALLOIMMUNIZATION; ANTIBODY DETECTION; BLEEDING; BRAIN HEMORRHAGE; CESAREAN SECTION; DISEASE MODEL; DISEASE SEVERITY; DRUG COST; DRUG MEGADOSE; FETUS; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; IMMUNE RESPONSE; INCIDENCE; INTRAUTERINE GROWTH RETARDATION; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN; NONHUMAN; OPSONIZATION; PATHOGENESIS; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; ANIMAL; FEMALE; IMMUNOLOGY; PERINATAL CARE; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFANT, NEWBORN; PERINATAL CARE; PREGNANCY; PRENATAL DIAGNOSIS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84957439805     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2015.12.004     Document Type: Review

References (99)

1. Junt T., Schulze H., Chen Z., Massberg S., Goerge T., Krueger A., et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007, 317(5845):1767-1770.
2. Ruggeri Z.M. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997, 78:611-616.
3. Hou Y., Carrim N., Wang Y., Gallant R.C., Marshall A., Ni H. Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. J Biomed Res 2015, 29:437-444.
4. Li C., Li J., Li Y., Lang S., Yougbare I., Zhu G., et al. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012, 2012:384685.
5. Murphy A.J., Bijl N., Yvan-Charvet L., Welch C.B., Bhagwat N., Reheman A., et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013, 19(5):586-594.
6. Wang Y., Andrews M., Yang Y., Lang S., Jin J.W., Cameron-Vendrig A., et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012, 12(2):126-132.
7. Ni H., Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci 2003, 28:257-264.
8. Yang H., Reheman A., Chen P., Zhu G., Hynes R.O., Freedman J., et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006, 4(10):2230-2237.
9. Jackson S.P. The growing complexity of platelet aggregation. Blood 2007, 109:5087-5095.
10. Ni H., Denis C.V., Subbarao S., Degen J.L., Sato T.N., Hynes R.O., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000, 106(3):385-392.
11. Roberts H.R., Hoffman M., Monroe D.M. A cell-based model of thrombin generation. Semin Thromb Hemost 2006, 32(Suppl 1):32-38.
12. Ni H., Papalia J.M., Degen J.L., Wagner D.D. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003, 102:3609-3614.
13. Wang Y., Reheman A., Spring C.M., Kalantari J., Marshall A.H., Wolberg A.S., et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014, 124(10):4281-4293.
14. Wang Y., Carrim N., Ni H. Fibronectin orchestrates thrombosis and hemostasis. Oncotarget 2015, 6:19350-19351.
15. Kumpel B.M., Sibley K., Jackson D.J., White G., Soothill P.W. Ultrastructural localization of glycoprotein IIIa (GPIIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008, 48:2077-2086.
16. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79(7):1157-1164.
17. Kim S.Y., Oh H.K., Ha J.M., Ahn H.Y., Shin J.C., Baek S.H., et al. RGD-peptide presents anti-adhesive effect, but not direct pro-apoptotic effect on endothelial progenitor cells. Arch Biochem Biophys 2007, 459(1):40-49.
18. McMillan R. Third annual review of immune thrombocytopenic purpura 2001, 5-8. Orlando.
19. Bussel J., Kaplan C., McFarland J. Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1991, 65:631-634.
20. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, 1(8634):363-366.
21. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1(8232):1228-1231.
22. Zeng Q., Zhu L., Tao L., Bao J., Yang M., Simpson E.K., et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012, 87(2):206-208.
23. Massey G.V., McWilliams N.B., Mueller D.G., Napolitano A., Maurer H.M. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987, 111:133-135.
24. Nieswandt B., Bergmeier W., Rackebrandt K., Gessner J.E., Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000, 96:2520-2527.
25. Webster M.L., Sayeh E., Crow M., Chen P., Nieswandt B., Freedman J., et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006, 108(3):943-946.
26. Li J., van der Wal D.E., Zhu L., Vadasz B., Simpson E.K., Li C., et al. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2013, 13(1):50-58.
27. Peng J., Ma S.H., Liu J., Hou Y., Liu X.M., Niu T., et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost 2014, 12(4):497-504.
28. Li J., Callum J.L., Lin Y., Zhou Y., Zhu G., Ni H. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 2014, 99:e61-e63.
29. Li J., van der Wal D.E., Zhu G., Xu M., Yougbare I., Ma L., et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015, 6:7737.
30. Bertrand G., Drame M., Martageix C., Kaplan C. Prediction of the fetal status in non-invasive management of alloimmune thrombocytopenia. Blood 2011, 117:3209-3213.
31. Kaplan C., Ni H., Freedman J. Alloimmune thrombocytopenia. Platelets 2013, 953-970. Elsevier/Academic Press, San Diego. 3rd ed. A.D. Michelson (Ed.).
32. Mueller-Eckhardt C., Kiefel V., Grubert A. High-dose IgG treatment for neonatal alloimmune thrombocytopenia. Blut 1989, 59:145-146.
33. Bussel J. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and posttransfusion purpura 2000, Churchill Livingstone, New York.
34. Bussel J.B., Zabusky M.R., Berkowitz R.L., McFarland J.G. Fetal alloimmune thrombocytopenia. N Engl J Med 1997, 337:22-26.
35. Vadasz Brian P.C., Yougbaré I., Zdravic D., Li J., Li C., Carrim N., et al. Platelets and platelet alloantigens: lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. Genes Dis 2015, 2(2):173-185.
36. von dem Borne A.E., Decary F. Nomenclature of platelet-specific antigens. Hum Immunol 1990, 29:1-2.
37. Newman P.J. Nomenclature of human platelet alloantigens: a problem with the HPA system?. Blood 1994, 83:1447-1451.
38. Group HI. Immuno polymorphism database. Available at: [accessed November 20, 2015]. http://www.ebi.ac.uk/ipd/hpa/table2.html.
39. Silva F., Morais S., Sevivas T., Veiga R., Salvado R., Taborda A. Severe intracranial haemorrhage in neonatal alloimmune thrombocytopenia. BMJ Case Rep 2011 Sep 4, 2011. pii: bcr0720114563. 10.1136/bcr.07.2011.4563.
40. Ohto H., Miura S., Ariga H., Ishii T., Fujimori K., Morita S. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004, 14:399-408.
41. Li C., Piran S., Chen P., Lang S., Zarpellon A., Jin J.W., et al. The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011, 121(11):4537-4547.
42. Xu X., Ye X., Xia W., Liu J., Ding H., Deng J., et al. Studies on CD36 deficiency in South China: two cases demonstrating the clinical impact of anti-CD36 antibodies. Thromb Haemost 2013, 110(6):1199-1206.
43. Curtis B.R., Ali S., Glazier A.M., Ebert D.D., Aitman T.J., Aster R.H. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002, 42:1173-1179.
44. Wu G.G. Detection of clinically relevant platelet antibodies in the Asian population. ISBT Sci Ser 2014, 9:112-117.
45. Kjeldsen-Kragh J., Killie M.K., Tomter G., Golebiowska E., Randen I., Hauge R., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007, 110(3):833-839.
46. Titze T.L.L.B., Vaage J.T., Killie M.K., Kjeldsen-Kragh J. HLA-DRB30101 exhibits a dose-dependent impact on maternal HPA 1a-antibody levels in HPA 1a-immunized women. Vox Sang 2011, 95:411.
47. Ahlen M.T., Husebekk A., Killie M.K., Skogen B., Stuge T.B. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB30101-restricted CD4+ T cells. Blood 2009, 113:3838-3844.
48. Yazdanbakhsh K., Zhong H., Bao W. Immune dysregulation in immune thrombocytopenia. Semin Hematol 2013, 50(Suppl. 1):S63-S67.
49. Aslam R., Hu Y., Gebremeskel S., Segel G.B., Speck E.R., Guo L., et al. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 2012, 120(10):2127-2132.
50. Nishimoto T., Satoh T., Simpson E.K., Ni H., Kuwana M. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost 2013, 11:369-372.
51. Ma L., Simpson E., Li J., Xuan M., Xu M., Baker L., et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 2015, 126(2):247-256.
52. Chen P., Li C., Lang S., Zhu G., Reheman A., Spring C.M., et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010, 116(18):3660-3668.
53. Ghetie V., Ward E.S. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000, 18:739-766.
54. Webster M.L., Zhu G., Li Y., Ni H. Fc-independent phagocytosis: implications for intravenous IgG therapy in immune thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2008, 8:278-282.
55. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
56. Kapur R., Kustiawan I., Vestrheim A., Koeleman C.A., Visser R., Einarsdottir H.K., et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014, 123(4):471-480.
57. Yougbare I., Zdravic D., Ni H. Angiogenesis and bleeding disorders in FNAIT. Oncotarget 2015, 6:15724-15725.
58. Palumbo J.S., Zogg M., Talmage K.E., Degen J.L., Weiler H., Isermann B.H. Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost 2004, 2:1368-1379.
59. Yougbare I., Lang S., Yang H., Chen P., Zhao X., Tai W.S., et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 2015, 125(4):1545-1556.
60. Ni H., Chen P., Spring C.M., Sayeh E., Semple J.W., Lazarus A.H., et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006, 107(7):2976-2983.
61. Ghevaert C., Wilcox D.A., Fang J., Armour K.L., Clark M.R., Ouwehand W.H., et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 2008, 118(8):2929-2938.
62. Bakchoul T., Boylan B., Sachs U.J., Bein G., Ruan C., Santoso S., et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009, 49(2):265-270.
63. Chow L., Aslam R., Speck E.R., Kim M., Cridland N., Webster M.L., et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010, 115(6):1247-1253.
64. Bowman J., Harman C., Mentigolou S., Pollock J. Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet 1992, 340(8826):1034-1035.
65. Roopenian D.C., Christianson G.J., Sproule T.J., Brown A.C., Akilesh S., Jung N., et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003, 170(7):3528-3533.
66. Li C., Chen P., Vadasz B., Ma L., Zhou H., Lang S., et al. Co-stimulation with LPS or Poly I: C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia. Thromb Haemost 2013, 110(6):1250-1258.
67. Butros L.J., Bussel J.B. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 2003, 25:660-664.
68. Tiller H., Killie M.K., Husebekk A., Skogen B., Ni H., Kjeldsen-Kragh J., et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand 2012, 91(1):79-86.
69. Yougbaré Issaka W-ST., Zdravic D., Vadasz B., Marshall A., Chen P., Zhu G., et al. Pathology of placenta in fetal and neonatal immune thrombocytopenia: Roles of Th17 immune responses, anti-platelet antibodies and angiogenic factors. J Thromb Haemost 2015, 13(S2).
70. Tiller H., Killie M.K., Chen P., Eksteen M., Husebekk A., Skogen B., et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012, 52(7):1446-1457.
71. Tiller H., Killie M.K., Skogen B., Oian P., Husebekk A. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 2009, 116(4):594-598.
72. Killie M.K., Husebekk A., Kjeldsen-Kragh J., Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008, 93:870-877.
73. Socher I., Andrei-Selmer C., Bein G., Kroll H., Santoso S. Low-avidity HPA-1a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface plasmon resonance technology. Transfusion 2009, 49(5):943-952.
74. Scheffer P.G., Ait Soussan A., Verhagen O.J., Page-Christiaens G.C., Oepkes D., de Haas M., et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011, 118(11):1392-1395.
75. Rayment R., Brunskill S.J., Soothill P.W., Roberts D.J., Bussel J.B., Murphy M.F. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011, (5):CD004226.
76. Imbach P., Lazarus A.H., Kuhne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang 2010, 98(3 Pt 2):385-394.
77. Hansen R.J., Balthasar J.P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002, 88:898-899.
78. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nature Med 2006, 12:688-692.
79. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320(5874):373-376.
80. Rossi K.Q., Lehman K.J., O'Shaughnessy R.W. Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. J Matern Fetal Neonatal Med 2015, 1-6.
81. Kaplan C., Murphy M.F., Kroll H., Waters A.H. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids - more questions than answers. European Working Group on FMAIT. Br J Haematol 1998, 100:62-65.
82. Paridaans N.P., Kamphuis M.M., Taune Wikman A., Tiblad E., Van den Akker E.S., Lopriore E., et al. Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trial. Fetal Diagn Ther 2015, 38(2):147-153.
83. Bussel J.B., Berkowitz R.L., Hung C., Kolb E.A., Wissert M., Primiani A., et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010, 203(2). 135.e1-e14.
84. Bussel J.B., Berkowitz R.L., McFarland J.G., Lynch L., Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988, 319:1374-1378.
85. Nicolini U., Tannirandorn Y., Gonzalez P., Fisk N.M., Beacham J., Letsky E.A., et al. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia. Am J Obstet Gynecol 1990, 163(4 Pt 1):1144-1146.
86. Urbaniak S.J., Duncan J.I., Armstrong-Fisher S.S., Abramovich D.R., Page K.R. Variable inhibition of placental IgG transfer in vitro with commercial IVgG preparations. Br J Haematol 1999, 107:815-817.
87. Kjeldsen-Kragh J., Husebekk A., Kiar Killie M., Skogen B. The pathophysiology of FNAIT cannot be deduced from highly selected retrospective data. Blood 2011, 118:2638-2639.
88. Vinograd C.A., Bussel J.B. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica 2011, 95:1807-1811.
89. Bertrand G., Petermann R., Kaplan C. Prediction of IVIG treatment efficiency in fetal/neonatal alloimmune thrombocytopenia. Blood 2014, 124:654-655.
90. Letsky E.A., Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol 1996, 95:21-26.
91. Kroll H. Intravenous IgG during pregnancy for fetal alloimmune thrombocytopenic purpura?. Thromb Haemost 1993, 69:1625.
92. Daffos F., Capella-Pavlovsky M., Forestier F. Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: a study of 606 consecutive cases. Am J Obstet Gynecol 1985, 153:655-660.
93. Ouwehand W.H., Smith G., Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn. Archs Dis Childh Fetal Neonatal Ed 2000, 82:F173-F175.
94. Bussel J.B., Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev 2008, 22:33-52.
95. Bassler D., Greinacher A., Okascharoen C., Klenner A., Ditomasso J., Kiefel V., et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion 2008, 48(1):92-98.
96. Kiefel V., Bassler D., Kroll H., Paes B., Giers G., Ditomasso J., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006, 107(9):3761-3763.
97. Allen D., Verjee S., Rees S., Murphy M.F., Roberts D.J. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood 2007, 109:388-389.
98. Bakchoul T., Sachs U.J., Wittekindt B., Sclosser R., Bein G., Santoso S. Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets. Pediatr Blood Cancer 2008, 50:1293-1294.
99. Kjeldsen-Kragh J., Ni H., Skogen B. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol 2012, 19:469-474.